 | | Vol. 6.29 – 7 August, 2020 |
| |
|
|
| Intestinal organoids were grown from rectal biopsies in a cohort of 97 subjects with cystic fibrosis. Residual CFTR function was measured by quantifying organoid swelling induced by forskolin and response to modulators by quantifying organoid swelling induced by CFTR correctors, potentiator and their combination.
[European
Respiratory Journal] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Mice lacking intestinal TLR9 had profoundly increased liver injury after hepatic ischemia reperfusion (IR) compared to WT mice with exacerbated hepatocyte necrosis, apoptosis, neutrophil infiltration, and inflammatory cytokine generation. They also observed increased small intestinal inflammation and apoptosis after hepatic IR in intestinal TLR9 deficient mice. Fecal short‐chain fatty acids butyrate and propionate levels were lower in intestinal TLR9 deficient mice.
[FASEB Journal] |
|
|
|
| Scientists found that deletion of Erk1/2 in intestinal epithelial cells at embryonic stages resulted in an unexpected increase in cell proliferation and migration, expansion of intestinal stem cells and formation of polyp-like structures, leading to postnatal death.
[Development] |
|
|
|
| Researchers found that STK4 knockdown enhanced sphere formation and metastasis in vitro and promoted tumor development in vivo. STK4 colocalized with β‐catenin and directly phosphorylated β‐catenin resulting to its degradation via the ubiquitin‐mediated pathway.
[Molecular Oncology] |
|
|
|
| Y-27632 induced the acquisition of a pro-migratory cell phenotype and increased cancer cell invasiveness in both 3- and 2-dimensions assays. This effect was prevented by the inhibition of NaV1.5 voltage-gated sodium channel activity. ROCK inhibition enhanced the activity of the pro-invasive NaV1.5 channel through a pathway that was independent of gene expression regulation.
[Scientific Reports] |
|
|
|
| Investigators surveyed the expression levels and clinical significance of novel long noncoding RNAs related to CYP24A1 and PFDN4 genes in colorectal cancer using real‐time polymerase chain reaction. They also assessed the expression of these genes after vitamin D treatment in HCT‐116 and HT‐29 colon cancer cell lines.
[Journal of Cellular Physiology] |
|
|
|
| MIR503HG negatively regulated its target miR-107. MiR-107 overexpression reversed the anti-tumor effects of MIR503HG overexpression on colon cancer cells. Par4 was a target of miR-107, which was positively regulated by MIR503HG. The promoting effects of MIR503HG silencing on colon cancer cells were eliminated by Par4 overexpression.
[Experimental Cell Research] |
|
|
|
| In the wound healing assay, berberine exhibited the ability to promote cell migration, indicating that berberine could probably recover the function of intestinal epithelial cells when the intestinal epithelial barrier was damaged by the peritoneal dialysis fluid.
[Journal of Ethnopharmacology] |
|
|
|
| The three dihydroxystilbenes in this study inhibited colon carcinogenesis and tumor growth as well as increases in colon IL-1β, IL-6, MCP-1, and PD-1 levels in AOM/DDS-treated mice in vivo. The three dihydroxystilbenes also suppressed COX-2 expression in colon tumors in vivo and inhibited PD-1 elevations in M2-THP-1 macrophages in vitro.
[European Journal of Pharmacology] |
|
|
|
|
| The authors summarize the recent findings into how intestinal stem cell (ISC) identity can be defined by proliferation state, signaling crosstalk, epigenetics and metabolism, and propose an update on the hallmarks of ISCs. They further discuss how these properties contribute to intestinal development and the dynamics of injury-induced regeneration.
[Development] |
|
|
|
|
| Celltrion Healthcare announced that the European Commission has granted marketing authorization for Remsima® subcutaneous formulation for the treatment of adult patients with ankylosing spondylitis, Crohn’s disease, ulcerative colitis, psoriatic arthritis and psoriasis.
[Celltrion Healthcare ] |
|
|
|
| Hutchison China MediTech Limited and Eli Lilly and Company announced an amendment to the 2013 License and Collaboration Agreement on Fruquintinib with Lilly Shanghai. The 2020 Amendment covers the expansion of Chi-Med’s role in the commercialization of Elunate® in China.
[Hutchison China MediTech Limited] |
|
|
|
|
| November 2 – November 3
Virtual |
|
|
|
|
|
| | NCI Center for Cancer Research – Bethesda, Maryland, United States |
|
|
|
| | USC Lawrence J. Ellison Institute for Transformative Medicine – West Los Angeles, California, United States |
|
|
|
| | University of Kentucky – Lexington, Kentucky, United States |
|
|
|
| | Emory University – Atlanta, Georgia, United States |
|
|
|
| | Baylor College of Medicine – Houston, Texas, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
